hotspot -WSS

hotspot

author：leisure time 2025-09-29 01:35:54 - browse：3163

Seng Cheng has been working in gene therapy for nearly as long as gene therapy has been a field. As a young scientist in the early 1990s, he was part of one of three teams racing to develop a gene therapy for cystic fibrosis, a high-profile effort that resulted in national headlines, prestigious publications, and zero patients cured.

So he’s seen the field’s highs and lows. Lately, there have been a lot of both, including at Pfizer, the company Cheng called home until this summer. The pharma brought three potentially powerful gene therapies for muscular dystrophy and hemophilia into late-stage trials but, in January, chose to abandon a large portfolio of early stage candidates that relied on the same technology: adeno-associated viruses, or AAVs, a group of small bugs that scientists spent two decades taming into a gene shipping system.

The move seemed emblematic. Across the industry, AAV companies have been struggling, either shelving programs or stopping work altogether, while investors shuttled money toward new technologies such as CRISPR and its various permutations. Longtime researchers feared promising drugs, particularly for ultra-rare diseases, might get lost in the shuffle.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Medicare reduced heart disease by changing how it pays doctors

explore

hotspot

focus

WSS

Oprah kicked off a national conversation on obesity. Let's have it

Roche subsidiary Foundation Medicine opens new headquarters

States should stop sabotaging methadone treatment reform

Merck drug for rare lung condition set for approval in U.S.

Why health workers in Gaza are injured or die at high rates

Patient advocates debate FDA's accelerated approval process

hotspot

hotspot

hotspot

What does generative AI mean for health care? We asked experts

Lawmakers consider Medicare pay reforms for doctors

Novavax promises a turnaround & Lilly roils the obesity market

Why health workers in Gaza are injured or die at high rates

Anesthesiologist group: stop taking Ozempic before surgery

UnitedHealth’s board chair also owns a personal investment firm

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

FDA gives detailed accounting of AI

Dobbs anniversary: the lost opportunity of abortion as health care

Study says nonprofit hospitals fall short in charity care spending

hotspot

STAT Readout Newsletter: Today's biggest biotech updates

Beam Therapeutics to lay off 20% of its staff, re

Hospital price transparency does save money, advocate argues

How climate

Impact of Dobbs ruling felt at reproductive medicine meeting

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

explore

hotspot

focus

hotspot